title: Medical management of hypertrophic cardiomyopathy.
abstract: Hypertrophic cardiomyopathy (HCM) is the most common genetically transmitted cardiomyopathy. The underlying cause of HCM has been attributed to a number of mutations within genes encoding primarily for sarcomeric proteins, which lead to a heterogeneous phenotype of left ventricular hypertrophy in the absence of other causes (eg, hypertension, aortic stenosis, or a discrete membranous subaortic stenosis). Symptoms may range from mild to severely limiting and consist of dyspnea and chest pain with exertion or at rest, syncope, or even sudden cardiac death (SCD). The majority of patients with HCM are treated medically. The primary aim of therapy is to reduce symptoms, but it should also address the risk of SCD. Throughout the years, numerous medical treatments have been used to achieve symptom control in these patients, and include medications such as β-blockers, calcium channel blockers, amiodarone, disopyramide, and angiotensin receptor blockers. This review provides an overview of the current medical treatment of HCM.
authors.affiliation: Division of Cardiology and the Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
authors.forename: Jesse J
authors.initials: JJ
authors.lastname: Naghi
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Siegel
mesh_terms: D024741:Cardiomyopathy, Hypertrophic, Familial / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D016757:Death, Sudden, Cardiac / Q000517:prevention & control; D020022:Genetic Predisposition to Disease; D006801:Humans; D009154:Mutation; D010641:Phenotype; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents